{
    "clinical_study": {
        "@rank": "58875", 
        "arm_group": [
            {
                "arm_group_label": "Ascending single dose of OP0595", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to assess the safety, tolerability and pharmacokinetic\n      profile of OP0595 administered intravenously to healthy male, Caucasian, adult subjects at\n      single escalating doses."
        }, 
        "brief_title": "A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595", 
        "condition": [
            "Healthy Volunteers", 
            "Bacterial Infections"
        ], 
        "condition_browse": {
            "mesh_term": "Bacterial Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Caucasian males aged between 18 and 45 years (inclusive) at Screening\n\n          -  A Body Mass Index (BMI) between 18.0 and 30.0 kg/m\u00b2 (inclusive) at Screening\n\n          -  Good general health as determined by the Investigator based on medical history,\n             physical examination, vital signs, 12-lead ECG and clinical laboratory tests\n\n          -  Negative urine test for drugs of abuse and breath test for alcohol both at Screening\n             and Day -1\n\n        Exclusion Criteria:\n\n          -  Receipt of any investigational agent or drug within four months before Screening\n\n          -  A history or current evidence of allergic symptoms such as bronchial asthma,\n             drug-induced rash or urticaria\n\n          -  Hypersensitivity and/or allergy to drugs\n\n          -  Concurrent or history of clinically significant cardiovascular, hepatic, renal,\n             endocrine, gastrointestinal, respiratory, psychiatric, neurologic and/or\n             hematological disorders\n\n          -  A history of chronic or recurrent infections or current active infection\n\n          -  A recent history of surgery within three months prior to Screening, determined by the\n             Investigator to be clinically relevant\n\n          -  A history or presence of malignancy\n\n          -  Donation of blood (or loss of blood) greater than 400 ml within three months before\n             Screening\n\n          -  A history of smoking at any time within one year before Screening"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134834", 
            "org_study_id": "OP0595-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ascending single dose of OP0595", 
                "description": "Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation", 
                "intervention_name": "OP0595", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "description": "Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 11, 2014", 
        "location": {
            "contact": {
                "last_name": "Janakan Krishnarajah", 
                "phone": "+61(8)63825100"
            }, 
            "facility": {
                "address": {
                    "city": "Perth,", 
                    "country": "Australia", 
                    "state": "Western Australia"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of OP0595 Administered Intravenously in Healthy Male Subjects.", 
        "overall_official": {
            "affiliation": "Meiji Seika Pharma Co., Ltd.", 
            "last_name": "Mitsuharu Egawa", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients with adverse events", 
            "measure": "Safety from baseline through the end of the study", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 to Day 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134834"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Cmax, tmax, AUC0-last, AUC0-inf, Kel, T1/2, CLtot, Vdss", 
                "measure": "Plasma PK parameters of OP0595 and its metabolites", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 2"
            }, 
            {
                "description": "Ae, Ae0-t, Ae0-t/Dose, CLr", 
                "measure": "Urine PK parameters of OP0595 and its metabolites", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 2"
            }
        ], 
        "source": "Meiji Seika Pharma Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meiji Seika Pharma Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}